John Moroney to Piperazines
This is a "connection" page, showing publications John Moroney has written about Piperazines.
Connection Strength
0.197
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
Score: 0.197